Female sexual dysfunction. Mental and Behavioural Disorders
Conditions
Interventions
All women were included at routine clinical visits and were treated with 2 tablets of Libicare®, one every 12 hours, daily for 2 months (9 weeks). Libicare® is an oral food supplement containing dry e
Sponsors
Instituto Palacios de Salud y Medicina de la Mujer
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Healthy, postmenopausal women (no natural menses for at least 1 year) aged = 45 and = 65. Hysterectomized patients should have an FSH level above 40 IU. 2. Stable partner, living together for at least 15 days a month and being sexually available. 3. Risk of sexual dysfunction established at FSFI score< 25.83. 4. Integrity of the vaginal mucosa (without lesions or bleeding). 5. Women willing to and capable of understanding and signing an informed consent after receiving an explanation on the nature of the whole study. 6. Consenting to participate in the study and signing the Informed Consent form. 7. No desire for pregnancy in the next 3 months.
Exclusion criteria
Exclusion criteria: 1. Pregnant women or with suspected pregnancy. 2. Within 3 months following delivery or abortion. 3. Breastfeeding women. 4. Women with severe pain in sexual relationships (DMS-V). 5. Non-diagnosed abnormal genital bleeding or presence of vaginal lesions. 6. Women with symptoms of vaginal infection or signs of any other genital infection. 7. Women allergic or hypersensitive to the components of the study treatment. 8. Severe psychiatric disorder. 9. Use of any hormonal treatment with estrogens, progestogens, or estrogens and progestogens within 3 previous months prior to selection. 10. Use of any other drug or experimental device within 30 days prior to selection. • Any condition preventing the patient from participating in the study, at the researcher’s discretion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sexual function measured using Female Sexual Function Index (FSFI) at 9 weeks vs baseline. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. FSFI score for each domain at 9 weeks vs baseline. 2. Levels of free testosterone and sex hormone binding globulin at 9 weeks vs baseline. | — |
Countries
Spain
Outcome results
None listed